Hemogenyx Pharmaceuticals Share Discussion Threads

[purple11] 12/11/2019 10:17

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that it will be presenting at the Annual Investival Showcase to be held on November 19, 2019 at Waldorf Hilton Hotel, London.

Dr Vladislav Sandler, Chief Executive Officer, is scheduled to present on Tuesday, November 19 at 2:45 p.m., with one-on-one meetings to be held throughout the conference.

The Investival Showcase ( continues its exclusive partnership with global investment bank Jefferies, with the showcase co-located with the Jefferies 2019 London Healthcare Conference. The Investival Showcase directly connects life sciences corporates with global capital. It offers the opportunity for a greater proportion of private and smaller cap public companies to be a part of the biggest week in European life sciences investment. It provides the opportunity to pitch, profile and connect with investment partners brought together in London by both LSX, and Jefferies.

[purple11] 12/11/2019 10:15

another presentation.maybe they are trying to force 'global pharma's hand by presenting to other institutions aswell.

[purple11] 06/11/2019 09:01

anyway another presentation...

Presentation at the New York Oncology Investor Conference


Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that it will be presenting at the New York Oncology Investor Conference being held on November 12 and 13 in New York, New York.

Dr Vladislav Sandler, Chief Executive Officer, is scheduled to present on Tuesday, November 12 at 6:10 p.m., Eastern Time with one-on-one meetings to be held throughout the conference. The New York Oncology Investor Conference 2019 (www.oncologyinvestorconference.com) joins the leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies and cancer foundations for a discussion on trends, opportunities and risks in oncology investing. The conference will feature corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science.

[purple11] 06/11/2019 08:59

the market is stone cold dead.there is no volume anywhere.they just walk this down on tiny sells.where is the volume out there?

[on target] 05/11/2019 12:23

He's not going to update or 'give hints' until its signed off I reckon - too many close shaves with revealing information in the past.
Which of course could come at any time.

[idontflykathy] 05/11/2019 08:49

I guess right time to add few.
But why no update from HEMO about collaboration or even IND news.

[johntopdog] 02/11/2019 12:59

I am a genius kathy

[davevt] 02/11/2019 12:13

I laughed every time you said this was a great share and argued with me, then told us you sold out and now agree with me. Then you started ramping your other shares on this thread.

Idiots everywhere 😅😅

[idontflykathy] 02/11/2019 00:47

John - seriously I think you’re either genius or idiot.

Cmon look at hemo history and tell us.

I’m not denying it’s a dodgy company for sure but cmon ;)

[davevt] 28/10/2019 15:37

Snakes eat mice...

[johntopdog] 25/10/2019 15:33

Mice are on aisle 1 Dave, but aisle 2 maybe of more interest to you , which is where the snakes are kept !

[davevt] 25/10/2019 14:58

I see the glorified pet shop has sold some more mice..

[johntopdog] 25/10/2019 14:19

This is the HEMO board Kathy...not the NFX board !

[idontflykathy] 25/10/2019 10:48

NFX up 45%!!! Since i sold HEMO and invested in NFX it's up like 60% in like 2 weeks

[johntopdog] 23/10/2019 15:52

So what exactly are they researching with this new agreement?

[elpirata] 23/10/2019 10:19

anyone got access to todays share price Angel hemo note?

[badger60] 23/10/2019 09:06

I think that Vlad is a bit naive when it comes to corporate governance etc.. He's a brilliant scientist with possibly a bit of an ego problem?

[digittt] 23/10/2019 08:51

Isn't the RNS just because he wants to talk about it at the conference someone mentioned earlier that's happening yesterday / today?

Realise it's a naff non-RNS regardless, but may have been what drove his behaviour.

Do not like the fact that he is blocking folks on Twitter...at least one of which are raging bulls on his stock...that doesn't bode well to me. And no, it's not me.

[badger60] 23/10/2019 08:41

Well.....at least they have done something that has substantively generated income......albeit only $75k. More important is that it's another brick in the wall re. customer/product development progress.Fwiw in an early YouTube vid where they were awarded $250k I seem to remember an estimated full year 2020 earnings of $30mio with a profit of $7 mio.

[seanlander] 23/10/2019 08:33

Could be a clever entry point. Worth a punt. I'm in at 2.9p but feel it's a good investment knowing what's happening in the background.

[tsmith2] 23/10/2019 07:13

a bit of news

[davevt] 21/10/2019 18:03

'Probably terrified of giving away price sensitive information (e.g. about the massive inlicensing deal being worked on'

It's not price sensitive is it, as he has already disclosed he was trying to work on a licensing deal.

Or maybe he was just ramping.

This is the problem with the doctor. And people are getting wise to this. He is pre releasing 'future news' in and rns. Pretty stupid don't you think, surely you'd keep it secret.....or it's just a ramp at the time to try and boost the share price. End of the day, even if it was true, he is under no obligation to say it never came to fruition.

Anyone can say in an rns 'we are currently working on a massive deal'.

[elpirata] 21/10/2019 12:40

I can well understand Dr Vlad concentrating on the business case as the IP partnerships evolve, rathar than become distracted with the short term share price -hemo is after all still a start up in relative sector terms.

However pre clinical stage biotech remains an activist fund sector & this is where share price Angel should be out there presenting the investment case on behalf of hemo - eg the US RW Venture Fund is listing in London on 30th with up to £277m to invest in biotech startups, the Vulpes life sciences funds have material stakes in a real mixed bag of AIM co's - most recently Scancell £3.9m injected in June. Hemo still needs to be actively promoted to the fund sector notwithstanding incoming anticipated big pharma news this quarter.